# Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III

> **Open Intelligence Dossier** · First detected: 2026-09-02 17:07 UTC · Category: Business

## Executive Summary
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III" is generating significant coverage in the Business category, with 1 articles from 1 distinct sources tracked by PULSE so far.


Outlets currently covering the story include Global Biodefense. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| Global Biodefense | GSK’s mRNA Flu Vaccine Heads to Phase III | [Source Link](https://news.google.com/rss/articles/CBMiiAFBVV95cUxPZUxmSjRzcGFSalZETE53WnJTcVBwQkhaSXJMZ19Ia0V6R2hKR3JnNjN0UXdBdDJac0wyalJqb0o0TFJMajJ3Z2R6dlc4eTRiUWItcVB4ajVFem1VUmh0VU93MHhfRXVnMHNSU0s4djRjR21YWWxrRU1KRnptbEI3dHdpNXJzVXNR?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-09-02/moderna-rises-6-despite-gsk-moving-rival-mrna-flu-vaccine-to-phase-iii*